| Name | Title | Contact Details |
|---|
Fogo de Chão is a Brazilian chain of churrascarias, or steakhouses, founded in 1979 in Porto Alegre, Brazil. The restaurant specializes in the traditional gaucho method of churrasco, which involves fire-roasting high-quality meats over an open flame. The founders, who grew up in Brazils Serra Gaúcha region, opened their first restaurant to share this culinary heritage. The company expanded to the U.S. in 1997 and has since grown to approximately 76 locations worldwide, including 59 in the U.S. The dining experience at Fogo de Chão features continuous service, where Gaucho chefs carve skewers of freshly grilled meats at the table. The all-you-can-eat menu includes up to 16 types of meats, along with a market table of salads and traditional Brazilian sides. The restaurant promotes a casual dining atmosphere, welcoming guests to enjoy a cultural Brazilian experience without a formal dress code. Fogo de Chão is committed to sourcing and preparing ingredients with respect for food, reflecting its rich culinary traditions.
Hancock and Moore Fine Furniture
Safety National is a prominent specialty insurance and reinsurance provider with over 80 years of experience. As a wholly-owned subsidiary of Tokio Marine Holdings, Inc., it benefits from the strength of one of the worlds top insurance groups. The company focuses on building strong relationships and providing long-term solutions for its customers. Safety National specializes in long-term insurance and reinsurance solutions, particularly in managing high-exposure claims. It offers MAP Client Services®, a suite of online risk control resources designed to help policyholders improve their safety and compliance programs. The company is highly rated by major financial agencies, holding an A++ rating from A.M. Best and an A+ rating from Standard & Poor’s. The corporate culture at Safety National emphasizes diversity, equity, and inclusion, aiming to reflect the communities it serves. The company is committed to corporate social responsibility through sustainability practices and charitable efforts. Safety National actively seeks talented individuals who share its dedication to excellence and growth.
At CounselX, we carefully listen to your unique needs and aspirations, showing our dedication to solve your three hard problems: Facilitating Enterprise Client and Law firms: Connecting enterprise clients with specialized legal talent for efficient outsourcing of specific legal tasks. This is me: https://shorturl.at/ctELY Supporting Legal Professionals: Offering a platform for legal experts to find flexible, additional work opportunities that utilize their skills and experience. This is me: https://shorturl.at/eqsAD Empowering Startups: Providing subscription-based legal services to help startups establish strong legal foundations and focus on growth through on-going support. This is me: https://shorturl.at/asKOT
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.